Study of Factors Regulating Mast Cell Proliferation

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT00044122
Collaborator
(none)
550
1

Study Details

Study Description

Brief Summary

This study will examine growth factors that promote and inhibit mast cell proliferation resulting in mastocytosis, a disease of excessive mast cells in the body. These cells can release chemicals that cause itching, blisters, flushing, bone pain and abdominal pain.

Patients up to 80 years of age with mastocytosis may be eligible for this 1-day study. Participants will have one visit at NIH lasting up to 8 hours, during which they will undergo the following tests and procedures:

  • Medical history and physical examination.

  • Laboratory studies, if medically indicated.

  • Blood tests to identify genetic changes important in the growth, development, and functioning of mast cells.

  • Bone marrow aspiration and biopsy.

For the bone marrow procedure, the skin over the hipbone and the outer surface of the bone itself are numbed with local anesthesia. Then, a special needle is inserted into the hipbone and about 1 tablespoon of bone marrow is drawn into a syringe. Another needle is inserted into the same area to collect a small piece of the bone marrow. Additional procedures may include allergen testing, urinalysis, and 24-hour urine collection.

Participants will receive an evaluation of their mastocytosis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This protocol is designed to examine those growth potentiating and inhibiting factors which regulate mast cell number and survival in patients with mastocytosis, and to explore the molecular basis of the disease process in hopes of improving therapy. Patients will carry the diagnosis of mastocytosis based on abnormal bone marrow biopsy and aspirate, abnormal skin biopsy, presence of urticaria pigmentosa, and if available, elevated serum tryptase level > 20 ng/ml and the presence of aberrant mast cell morphology and surface markers of CD2 and CD25. Mastocytosis patients will include children and adults from zero years to 80 years of age. Unaffected relatives (age 2 to 80 years) may also be enrolled. The protocol is designated for up to a 1-year enrollment period; with only a small number of enrolled patients that will stay on study for more than one visit, based on investigator assessment of contribution to study objectives. Participants will undergo standard physical exam, medical history review, and blood collection for clinical and research laboratory evaluations. We will collect clinical data and biological specimens for research evaluation from individuals undergoing clinically indicated diagnostic procedures. Some patients may participate in research evaluations including buccal swab collection, dietary intake assessment, stool collection, exercise challenge, microbiome studies, and activity tracking. These studies are optional. Patients may be asked to re-enter this protocol at a later time for further follow-up.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    550 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells
    Actual Study Start Date :
    Sep 18, 2002

    Arms and Interventions

    Arm Intervention/Treatment
    Adult Relatives

    Relatives of patient with mastocytosis

    Adults with Mastocytosis

    Adults with documented mastocytosis

    Pediatric Patients with Mastocytosis

    Pediatric patients with documented mastocytosis

    Pediatric Relatives

    Pediatric relatives of patients with mastocytosis

    Outcome Measures

    Primary Outcome Measures

    1. To obtain normal and neoplastic human mast cells from the bone marrow and peripheral blood of patients with mastocytosis in order to study the regulation of the proliferation and survival of these cells, and to assess the extent and classificati... [Patients return to NIH as necessary]

      continuing collection of cells from subjects with mastocytosis for ongoing experimentation in laboratory

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    • PATIENT PARTICIPANT INCLUSION CRITERIA:

    Participants with mastocytosis zero to 80 years of age may participate in telehealth visits, and two to 80 years of age may participate on-site at NIH Clinical Center.

    Histologic evidence of increased mast cell number by bone marrow and/or skin biopsy or documentation of mastocytosis in the skin

    supported with a photograph of diagnostic skin lesion

    Must be under the care of a primary care physician to be enrolled.

    Ability to provide informed consent.

    PATIENT PARTICIPANT EXCLUSION CRITERIA:

    Anemia with hemoglobin less than 8 g/dL, hematocrit less than 24.

    Any condition that in the opinion of the investigator contraindicates participation in this study.

    RELATIVE INCLUSION CRITERIA:

    Two to 80 years of age.

    A biological relative without the diagnosis of mastocytosis by skin examination or histologic evidence in a skin or bone marrow biopsy

    Participant has a primary medical care provider outside the NIH

    Ability to provide informed consent.

    RELATIVE EXCLUSION CRITERIA:

    Any condition that in the opinion of the investigator contraindicates participation in this study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institute of Allergy and Infectious Diseases (NIAID)

    Investigators

    • Principal Investigator: Hirsh D Komarow, M.D., National Institute of Allergy and Infectious Diseases (NIAID)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Institute of Allergy and Infectious Diseases (NIAID)
    ClinicalTrials.gov Identifier:
    NCT00044122
    Other Study ID Numbers:
    • 020277
    • 02-I-0277
    First Posted:
    Aug 19, 2002
    Last Update Posted:
    Aug 5, 2022
    Last Verified:
    Aug 2, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 5, 2022